Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study

NCT06100718 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT06100718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06100718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2022
Completion date
December 31, 2025
Enrollment
370 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer-related stroke, d-dimer, embolic stroke of undetermined source, ischemic stroke, occult cancer, paraneoplastic coagulopathy